Zai Lab Limited Stock (NASDAQ: ZLAB) Today: Pre‑Market Watchlist After China’s COBENFY Approval, NRDL Renewals, and Fresh Pipeline Catalysts
That timing matters today because Zai Lab Limited is entering the session with multiple company-specific catalysts on the board—most notably China’s approval of COBENFY for schizophrenia, plus updates tied to China’s National Reimbursement Drug List and progress in a key oncology program. Business Wire
